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Signiﬁcant advancements in protein engineering and DNA technology have seen biocatalytic
transformations take the place of traditional chemical manipulations in both academia and industry
for the preparation of active pharmaceutical ingredients (APIs) and other medicinally relevant
compounds. However, despite the large repertoire of commercially available biocatalysts that are
readily accessible, enzymes which mediate the formation of C–C bonds and those that enable
convergent synthesis remain largely undeveloped. To expand the scope of biocatalytic retrosynthesis
and enable it to complement traditional chemical retrosynthesis it is essential to develop a ‘toolbox’
of biocatalysts which build molecular complexity. Of particular interest is the development of one-pot
enzymatic cascades for the synthesis of functionalised, chiral building blocks without the need for
protecting group manipulations or harsh reaction conditions. Highly regio- and stereoselective
chemoenzymatic cascades have been developed for the synthesis of a range of chiral amines
employing ω-transaminases and monoamine oxidase variants.
& 2015 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).Contents
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Nature boasts an extraordinary variety of biocatalysts that
have the ability to mediate synthetically challenging transfor-
mations with exceptional levels of regio- and stereoselectivity.
These properties, coupled with advances in protein engineer-
ing and DNA technologies, mean that enzymes represent
important alternatives to more traditional chemical catalysts
(Reetz, 2013; Turner and O’Reilly, 2013). Directed evolution
has allowed the substrate range, stability and kinetic proper-
ties of enzymes to be tailored and means that we no longer
rely solely on their natural activity (Turner, 2009). Addition of
enzymes to the catalytic “toolbox”, including a diverse range
of commercially available biocatalysts (Figure 1), has enabled
chemists to redesign synthetic routes to important target
structures including bioactive natural products and active
pharmaceutical ingredients (APIs), providing more efﬁcient
and cost-effective syntheses. A number of chemoenzymatic
routes to the blockbuster API, Lipitor, have been developed
including ketoreductase-, nitrilase-, halohydrin dehalogenase-
and aldolase-mediated transformations and these diverse
approaches are testament to the broad synthetic utility of
biocatalysts (Figure 2) (Ma et al., 2010; Reetz, 2013).
Chiral amines are prevalent motifs in drug molecules and
the development of efﬁcient synthetic routes to optically
pure derivatives remains a fundamental goal for the pharma-
ceutical industry. ω-transaminases (ω-TAs) and variants of
monoamine oxidase from Aspergillus niger (MAO-N) repre-
sents two important families of biocatalysts for the produc-
tion of optically pure chiral amines. TAs can mediate the
reductive amination of pro-chiral ketones and allow access to
the corresponding (S)- or (R)-amines in high optical purity
(Frodsham et al., 2013; Höhne and Bornscheuer, 2009;
Koszelewski et al., 2010; Mathew and Yun, 2012; SavileFigure 1 Examples of commercially availableet al., 2010). Recognising their potential, Merck and Codexis
have engineered an (R)-selective ω-TA which has replaced a
rhodium-catalysed asymmetric enamine hydrogenation in the
industrial production of the oral antihyperglycemic drug,
Sitagliptin (Figure 3) (Savile et al., 2010).
MAO-N catalyses the oxygen-dependent conversion of
amines to imines (Alexeeva et al., 2002; Carr et al., 2003;
Dunsmore et al., 2006; Ghislieri et al., 2013a, 2013b;
Li et al., 2012; Rowles et al., 2012; Znabet et al., 2010)
and has been extensively engineered to accommodate a
diverse range of architectures, including the API, boceprevir
(Li et al., 2012) (Figure 3) and related motifs. The hydrogen
peroxide produced following oxidation has contributed
towards the successful evolution of MAO-N as it has enabled
the development of a highly effective high-throughput
screen that is substrate independent (Figure 4).Chemo-enzymatic cascade for the regio- and
stereoselective synthesis of 2,5-disubstituted
pyrrolidines
Enzymatic and chemo-enzymatic cascades involving the com-
bination of several enzymatic transformations in a concurrent
one-pot process allow complex molecular architectures to be
accessed with high optical purity, under ambient conditions
and without the need for costly intermediate puriﬁcation steps
or protecting group manipulations (Oroz-Guinea and García-
Junceda, 2013; Ricca et al., 2011; Schrittwieser et al., 2011).
Elegant cascades employing both ω-TAs (Oroz-Guinea and
García-Junceda, 2013; Ricca et al., 2011; Sattler et al., 2012;
Schrittwieser et al., 2011) and MAO-N variants (Alexeeva
et al., 2002; Carr et al., 2003; Dunsmore et al., 2006;
Ghislieri et al., 2013a, 2013b; Li et al., 2012; Rowlesenzymes from the ‘biocatalytic toolbox’.
Figure 2 Chemoenzymatic routes for the synthesis of the side-chain of Atorvastatin; KRED=ketoreductase; and HHDH=halohydrin
dehalogenase.
Figure 3 APIs Sitagliptin and Boceprevir accessed via a
chemoenzymatic route employing and engineered ω-TA and
MAO-N variants. Figure 4 A high-throughput colourimetric screen for mono-
amine oxidase activity employing horseradish peroxidase (HRP)
and a HRP substrate.
57Enzymatic cascades for the regio- and stereoselective synthesiset al., 2012; Znabet et al., 2010) have been reported for the
asymmetric synthesis of a range of important amine scaffolds
as well as for effective high-throughput screens. However,
until recently, a cascade involving a combination of these
two important amine synthesis enzymes had not been
explored.
Considerable efforts have focused on the development of
asymmetric routes to both cis- and trans-2,5-disubstituted
pyrrolidines as these structures represent important scaf-
folds in pharmaceutical drugs and natural products
(Aggarwal et al., 2004; Brenneman and Martin, 2004; Goti
et al., 2003; Hanessian et al., 2002; Severino and Correia,
2000; Trost et al., 2003; Xu et al., 2013; Zhang et al., 2007).
Accessing the trans-diastereomers via reduction of the
corresponding imine in high de is not straightforward and
led us to develop a tandam biocatalytic approach to their
synthesis. Our strategy (Figure 5) encompasses a highly
regio- and stereoselective TA mediated reductive amination
and spontaneous cyclisation followed by a diastereoselec-
tive chemo-enzymatic conversion to the corresponding
pyrrolidine using a combination of an (S)-selective MAO-N
variant and the non-selective reducing agent NH3 BH3
(O’Reilly et al., 2014a, 2014b).
We initially examined the reductive amination of non-
symmetrical diketone 1a with the commercially available(S)-selective ω-TA, ATA113, employing the lactate dehydro-
genase (LDH)/glucose dehydrogenase (GDH) system. Follow-
ing reductive amination exclusively on the sterically less
demanding methyl ketone, spontaneous cyclisation pro-
vided the corresponding 2,5-pyrroline 3a in excellent yield
and high optical purity (91% yield, 499% ee) (Figure 6a).
A novel transaminase (pf-ATA) from Pseudogulbenkiania
ferrooxidans was also explored which shares 95% sequence
identity with the transaminase from Chromobacterium
violaceum (cv-ATA) (ATCC 12472). pf-ATA also mediated
the reductive amination of diketone 1a, however, the
2,5-pyrroline 3a was obtained with a modest ee (75%).
Commercially available (R)-selective ATA117 catalysed the
regio- and stereoselective mono-amination of 1a affording
pyrroline (R)-3a in 65% yield and 499% ee (Figure 6b).
ATA113 and pf-ATA were then tested for their ability to
catalyse the reductive amination of a series of structurally
related diketones 1b–g (Table 1). ATA113 provided methyl-
substituted pyrrolines 3b–g as the sole regioisomers in
excellent conversion and high ee, while substitution of the
small methyl for a larger ethyl group resulted in a slightly
reduced ee (Table 1, entries 11 and 13). Pf-ATA provided
pyrrolines 3b–g in modest to poor ee and surprisingly,
Figure 5 Chemoenzymatic approach to the synthesis of chiral
2,5-disubstituted pyrrolidines (O’Reilly et al., 2014).
Figure 6 One-pot reductive amination of diketone 1a employing
(a) ATA113 and (b) ATA117. (a) Reductive amination with
(S)-selective transaminase and (b) Reductive amination with
(R)-selective transaminase.
Table 1 ω-TA mediated reductive amination of 3a–g.
Entry Substrate ω-TA Conv. [%] ee [%]
1 1a ATA113 499 499 (S)
2 1a PfATA 499 75 (S)
3 1b ATA113 499 499 (S)
4 1b PfATA 499 478 (S)
5 1c ATA113 499 499 (S)
6 1c PfATA 499 68 (S)
7 1d ATA113 499 499 (S)
8 1d PfATA 499 76 (S)
9 1e ATA113 499 499 (S)
10 1e PfATA 499 78 (S)
11 1f ATA113 60 96 (S)
12 1f PfATA 499 76 (R)
13 1g ATA113 499 94 (S)
14 1g PfATA 75 46 (R)
E. O'Reilly, N.J. Turner58replacement of the methyl substituent by ethyl resulted in a
switch in stereoselectivity, affording (R)-3f–g as the pre-
dominant enantiomers (Table 1, entries 12 and 14).
Kroutil and co-workers recently developed a chemo-
enzymatic route to related 2,6-disubstituted piperidines
employing an ω-transaminase followed by diastereoselec-
tive hydrogenation using Pd/C (Simon et al., 2012). The
same strategy is not effective for the synthesis of the ﬁve-
membered derivatives due to poor diastereoselectivity in
the reduction step and so we sought to employ MAO-N for a
chemo-enzymatic deracemisation. Two MAO-N variants (D5
and D9) were selected which have previously been evolved
to accept structurally related amine frameworks, including
pyrrolidines and piperidines. (S)- and (R)-3a were exposed
to NH3 BH3 in the presence of (S)-selective MAO-N, result-
ing in the accumulation of (2S,5R)- or (2R,5R)-pyrrolidine 4a
in excellent de (499%) following successive rounds of non-
selective reduction/(S)-selective oxidation (Figure 7). The
approach exploits the exquisite regio- and stereoselectivity
displayed by MAO-N which avoids stereorandomisation of
the C-2-stereocentre generated by the (S)-selective ω-TA.
Using the combination of NH3.BH3/MAO-N D9 allowed access
to 4b–g with excellent de (96–99%) (Table 2).
The compatibility of the ω-TA and MAO-N under the same
reaction conditions has also allowed the development of a
one-pot cascade (Figure 8) for the synthesis of target
(2S,5R)-4a in 82% isolated yield and 499% de. We have also
extended the one-pot TA/MAO-N approach for the prepara-
tion of (2S,5R)-4b, (2S,5R)-4d and (2S,5R)-4e in 499%
conversion and 499% de starting from the corresponding
diketones (Table 3), demonstrating the generality of this
one-pot approach.Monoamine oxidase/ω-transaminase cascade
for the deracemisation and dealkylation of
amines
While the deracemisation of cyclic amines using MAO-N
variants has proven to be an effective means of accessing
optically pure derivatives, employing this approach for the
deracemisation of acyclic derivatives is limited due to
competing hydrolysis of the imine in aqueous conditions.
We have exploited a MAO-N/ω-TA cascade which relies on
this competing hydrolysis for the effective deracemisation
of a panel of acyclic amines 5a–h (Figure 9, Table 4)
(O’Reilly et al., 2014a).
Optically pure MBA analogues have been employed as
chiral auxiliaries (O’Reilly et al., 2010a), for chiral deriva-
tisation (Chaudhari, and Suryaprakash, 2012) and for the
synthesis of peptides (O’Reilly et al., 2009; O’Reilly et al.,
2010b). The effective kinetic resolution of MBA-derivatives
using ω-TAs has been reported, although employing this
method for accessing optically pure amines results in a
maximum 50% yield. A two-step approach has been success-
fully used for the deracemisation of amines by exploiting
enantio-complementary TAs to achieve an initial resolution
followed by an asymmetric synthesis (Koszelewski et al.,
2009). Our approach takes advantage of a MAO-N mediated
enantioselective oxidation of the (S)-amine to the corre-
sponding ketone followed by reductive amination employing
an (R)-selective TA. Exploiting this method, optically
pure amines 5a–h can be accessed in high conversion and
499% ee. Further optimisation is ongoing with the aim of
reducing the quantity of expensive alanine donor employed
including the possibility of recycling the methyl-, ethyl- and
isopropylamine by-products formed during the dealkylation
Table 2 MAO/NH3 BH3 mediated asymmetric synthesis
of (2S,5R)-4a–g.
Entry Substrate MAO-N variant de [%] (2S,5R)
1 3a D5 499
2 3a D9 96
3 3b D5 88
4 3b D9 98
5 3c D5 499
6 3c D9 499
7 3d D5 499
8 3d D9 499
9 3e D5 68
10 3e D9 499
11 3f D5 64
12 3f D9 499
13 3g D5 56
14 3g D9 96
Figure 8 One-pot asymmetric synthesis of (2S,5R)-4a on
preparative-scale.
Table 3 ATA113/MAO-N one-pot cascade for the synth-
esis of (2S,5R)-4a–4b, and (2S,5R)-4d–e.
Ketone ω-TA MAO-N Conv. [%] de [%]
1aa ATA113 D5 499 499 (2S,5R)-4a
1bb ATA113 D9 499 499 (2S,5R)-4b
1db ATA113 D9 499 499 (2S,5R)-4d
1eb ATA113 D9 499 499 (2S,5R)-4e
a25 mM substrate concentration.
b5 mM substrate concentration.
Figure 9 MAO-N/ω-TA cascade for the overall dealkylation of
amines 5a–h.
Table 4 Deracemisation of racemic amines 1a–h using
a MAO-N/ω-TA cascade process.
Rac-1 Conversiona (%) ee (R)-enantiomer (%)
5a 99 499
5b 87 499
5c 91 499
5d 90 499
5e 99 499
5f 90 499
5g 90 499
5h 81 499
aConversion is based on conversion of the ketone.
Figure 7 MAO-N mediated synthesis of (2S,5R)-4a and
(b) (2R,5R)-4a.
59Enzymatic cascades for the regio- and stereoselective synthesisas an alternative amine donor source. The same method can
also be used for the regioselective dealkylation of amines.
Oxidation of N-alkyl amines 6a–c using MAO-N provided the
corresponding aldehyde, which was quantitatively con-
verted to 8 by the action of a commercially available (R)-
selective TA (ATA117) (Figure 10).Conclusion
The ﬁrst examples of the use of transaminases in combina-
tion with monoamine oxidase variants have been devel-
oped. The compatibility of these important amine synthesis
biocatalysts enables the regio- and stereoselective synthesis
of chiral 2,5-disubstituted pyrrolidine building blocks in
excellent conversion (499%) and de (96–99%). The same
Figure 10 MAO-N/ω-TA cascade for the overall dealkylation of
amines 6a–c.
E. O'Reilly, N.J. Turner60combination also enables the deracemisation and dealkyla-
tion of a range of methylbenzylamine derivatives. This
technology in combination with the expanding ‘toolbox’ of
transaminase and monoamine oxidase variants means that
this approach will have broad utility for the construction of
chiral amine frameworks.Conﬂict of interest
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